![Ruoxi Hu](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ruoxi Hu
Direktor/Vorstandsmitglied bei Firecyte Therapeutics, Inc.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
William E. Yelle | M | - |
Firecyte Therapeutics, Inc.
![]() Firecyte Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Firecyte Therapeutics, Inc. is an emerging biotechnology company based in Cambridge, MA that is focused on developing novel treatment strategies for progressive neurodegenerative diseases of the eye. The company's research is centered around the role of microglia and neuroinflammation in these diseases. The team is led by Jonathan Levenson, the Chief Scientific Officer, who has over 16 years of experience in neuropsychiatry, neurodegeneration, and neuroinflammation. The company was founded by Dong Feng Chen and William E. Yelle, who has been the CEO since incorporation. | - |
Meredith Fisher | M | - |
Firecyte Therapeutics, Inc.
![]() Firecyte Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Firecyte Therapeutics, Inc. is an emerging biotechnology company based in Cambridge, MA that is focused on developing novel treatment strategies for progressive neurodegenerative diseases of the eye. The company's research is centered around the role of microglia and neuroinflammation in these diseases. The team is led by Jonathan Levenson, the Chief Scientific Officer, who has over 16 years of experience in neuropsychiatry, neurodegeneration, and neuroinflammation. The company was founded by Dong Feng Chen and William E. Yelle, who has been the CEO since incorporation. | - |
Charles Kunsch | M | - |
Firecyte Therapeutics, Inc.
![]() Firecyte Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Firecyte Therapeutics, Inc. is an emerging biotechnology company based in Cambridge, MA that is focused on developing novel treatment strategies for progressive neurodegenerative diseases of the eye. The company's research is centered around the role of microglia and neuroinflammation in these diseases. The team is led by Jonathan Levenson, the Chief Scientific Officer, who has over 16 years of experience in neuropsychiatry, neurodegeneration, and neuroinflammation. The company was founded by Dong Feng Chen and William E. Yelle, who has been the CEO since incorporation. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 3 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen